Advertisement

Search Results for "Isogenica Press Release Framework"

08:32 EDT 24th May 2013 | BioPortfolio

Original Source: Isogenica secures European Framework 7 grant worth up to Euros 700,000

Cambridge, UK, 8 April 2012: Isogenica Ltd today announced that it had been successful in securing a Framework 7 grant for €700,000 over the next three years, part of a €5.55 million project with consortium grant funding of €3.99 million. The grant commenced in January 2012. The 10 consortium members are Apogenix GmbH, Biametrics GmbH, Center for Advanced Bioanalysis, German Cancer Research Centre, Isogenica, Karlsruher Institute for Technology (KIT), Microsystems LTD, PEPperPRINT, Tec...

Matching Channels

Synthesis and Release of Thyroid Hormones

Drug Delivery - news, views, blogs

Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals.  Drug delivery technologies are patent protected formulat...

Obinutuzumab

A glycoengineered, fully humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellula...

Disorders of Calcium Concentration

Calcium (Ca) is required for the proper functioning of muscle contraction, nerve conduction, hormone release, and blood coagulation. In addition, proper Ca concentration is required for various othe...

Stress

Stress is caused by your perception of situations around you and then the reaction of your body to them. The automatic stress response to unexpected events is known as 'fight or flight'. Dis...

Matching News

Isogenica secures European Framework 7 grant worth up to Euros 700,000

Cambridge, UK, 8 April 2012: Isogenica Ltd today announced that it had been successful in securing a Framework 7 grant for €700,000 over the next three years, part of a €5.55 million pr...

Isogenica announces new collaboration with Professor Sir Tom Blundell of the University of Cambridge. Isogenica and the University of Cambridge to apply leading edge molecular modelling to optimise Isogenica’s novel peptide scaffold libraries

Cambridge UK, 2 November 2010: Isogenica Ltd today announced that it has entered into a collaborative agreement with Professor Sir Tom Blundell of the University of Cambridge. The initial focus of...

RCT partners with Isogenica for large-scale screening of new antibody-derived scaffold platform

US company Research Corporation Technologies, Inc has formed a partnership with Cambridge, UK-based Isogenica to access Isogenica’s CIS display platform for the screening of proprietary libraries of...

Isogenica Ltd expands business development and customer support operations into North America

Californian office established to support existing and prospective customers Cambridge, UK 30 March 2011: Isogenica today announced that it has established a dedicated business development and cus...

Isogenica, Cresset Group and Biolauncher Secure Funding from UK's Technology Strategy Board for a £1M project to Develop New Small Molecule Drug Platform (News)

06 June 2012: Cambridge & Welwyn Garden City, UK - Isogenica and Biolauncher together with Cresset Group, announce funding from the Technology Strategy Board, the ...

Research Corporation Technologies, Inc., Partners with Isogenica for Large Scale Screening of a New Antibody-Derived Scaffold Platform

Research Corporation Technologies, Inc. (RCT), of Tucson, has partnered with Isogenica, of Cambridge, U.K., to access Isogenica’s CIS display platform for the screening of propr...

Isogenica announces latest board level appointment. Göran Forsberg, Chief Business Officer at Active Biotech joins Isogenica as non-executive Director.

Isogenica today announced the appointment of Göran Forsberg to the Board of Directors. Currently Chief Business Officer (CBO) at Active Biotech in Lund, Sweden, Göran brings extensive in...

Isogenica, Research Corporation Technologies Inc. deal

Matching PubMed Articles

Press release.

Targeted synthesis of a 2D ordered porous organic framework for drug release.

A novel 2D porous organic framework based on the nucleophilic substitution of cyanuric chloride has been designed and synthesized successfully, which possesses an ordered structure, permanent porosity...

Trapping Guests within a Nanoporous Metal-Organic Framework through Pressure-Induced Amorphization.

The release of guest species from within a nanoporous metal-organic framework (MOF) has been inhibited by amorphization of the guest-loaded framework structure under applied pressure. Thermogravimetri...

Neuronal activity reflecting progression of trials in the pre-supplementary motor area of macaque monkey: An expression of neuronal flexibility.

We studied the activity of single neurons in the pre-supplementary motor area (pre-SMA) of macaque monkeys as they performed two visuomotor tasks, called the visual fixation task and the visual fixati...

Press release and media distort complex message.

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement